CompletedNot Applicable

Endoscopic Treatment for Local Residual Neoplasia

Czechia25 participantsStarted 2013-10

Plain-language summary

Endoscopic mucosal resection (EMR) is considered to be a gold standard of therapy of colorectal lateral spreading tumors (LST) without significant risk for lymphatic spread. According to the investigators previous study, local residual neoplasia (LRN) after conventional endoscopic mucosal resection (EMR)occurs in up to 21% of cases. Endoscopic therapy of LRN was not sufficient in 53 % and has not been standardized yet.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients older than 18 years * patients with local residual neoplasia in scar in three months after endoscopic mucosal resection for laterally spreading tumor (0-IIa \> 10 mm) * signed informed consent Exclusion Criteria: * incomplete endoscopic mucosal resection * previous therapy for local residual neoplasia * difficult or impossible localization of post-EMR scar

What they're measuring

Efficacy of endoscopic treatment od local residual neoplasia (absence of neoplastic tissue in post-EMR scar proven by endoscopic and histologic examination)

Timeframe: 6 months

Trial details

NCT IDNCT02386618

SponsorVitkovice Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-06

View on ClinicalTrials.gov More Colorectal Cancer trials